Since it is difficult to produce infectious HPV particles for research, little has been known about HPV susceptibility to disinfection, said Craig Meyers, Distinguished Professor of Microbiology and Immunology, Penn State College of Medicine.
Use of disinfectants on HPV in health care settings has been based on what works on other viruses or what is thought should be effective, researchers said.
Meyers collaborated with Richard Robison, an expert in microbial disinfectants at Brigham Young University.
For this study, researchers grew HPV16, a specific strain that is responsible for up to 60 per cent of HPV-associated cancers. They then used 11 common disinfectants on the virus.
These disinfectants included ones made of ethanol and isopropanol because these are common ingredients in surface disinfectants and hand sanitisers used in both public and health care settings.
Study of these hand sanitisers is important because other research has shown high levels of HPV DNA on fingers of patients with current genital infections.
"Chemical disinfectants in hand sanitiser are commonly used in the general population to prevent the spread of infectious diseases," Meyers said.
"For flu or cold viruses they are very effective. But the data shows that they do nothing for preventing the spread of human papillomavirus," said Meyers.
They also tested other common disinfectants, including glutaraldehyde, which is used for sterilisation in medical and dental facilities. Results show that glutaraldehyde is not effective at inactivating the HPV virus.
Other research has suggested that HPV could be transmitted non-sexually. The current study shows that medical instruments considered sterile could pose a risk for transmission.
"So unless bleach or autoclaving is used in the hospital setting, human papillomavirus is not being killed and there is a potential spread of HPV through hospital acquired or instrument or tool infection," said Meyers.
Meyers said the results suggest a need for a change in disinfectant use policies.
The study was published in the Journal of Antimicrobial Chemotherapy.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
